pentamidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2090	100-33-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pentamidine isetionate pentamidine diisethionate pentamidine pentamidine isethionate pentamidin pentamidine mesylate pentamidine mesilate	Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. Molecular weight: 340.43 Formula: C19H24N4O2 CLOGP: 2.31 LIPINSKI: 0 HAC: 6 HDO: 4 TPSA: 118.20 ALOGS: -4.16 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pentamidine isetionate
pentamidine diisethionate
pentamidine
pentamidine isethionate
pentamidin
pentamidine mesylate
pentamidine mesilate

Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.

Molecular weight: 340.43
Formula: C19H24N4O2
CLOGP: 2.31
LIPINSKI: 0
HAC: 6
HDO: 4
TPSA: 118.20
ALOGS: -4.16
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.28	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	100 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	12 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	11.75 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	53 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	74 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.09 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	25 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 16, 1984	FDA	FRESENIUS KABI USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aplastic anaemia	118.79	23.66	39	4543	7664	50592878
Pneumocystis jirovecii pneumonia	118.63	23.66	46	4536	14617	50585925
Toxoplasmosis	112.30	23.66	26	4556	1391	50599151
Febrile neutropenia	84.07	23.66	70	4512	97597	50502945
Nocardiosis	82.46	23.66	21	4561	1677	50598865
Hypoalbuminaemia	69.45	23.66	28	4554	9832	50590710
Cytomegalovirus viraemia	65.23	23.66	22	4560	4687	50595855
Antinuclear antibody negative	65.07	23.66	12	4570	204	50600338
Antithrombin III	61.51	23.66	11	4571	156	50600386
Coombs positive haemolytic anaemia	59.67	23.66	12	4570	327	50600215
Herpes simplex reactivation	57.78	23.66	12	4570	385	50600157
Delayed graft function	57.70	23.66	14	4568	916	50599626
Pulmonary mucormycosis	51.95	23.66	10	4572	216	50600326
Lymphopenia	48.28	23.66	25	4557	15596	50584946
Graft versus host disease	45.11	23.66	18	4564	6148	50594394
Gastritis haemorrhagic	43.29	23.66	12	4570	1325	50599217
Antiphospholipid syndrome	41.79	23.66	12	4570	1505	50599037
Focal myositis	40.21	23.66	6	4576	24	50600518
Rhodococcus infection	39.64	23.66	7	4575	92	50600450
Complex regional pain syndrome	38.56	23.66	12	4570	1981	50598561
Cryptosporidiosis infection	37.79	23.66	8	4574	282	50600260
Escherichia bacteraemia	37.09	23.66	13	4569	3103	50597439
Mycobacterium avium complex infection	35.75	23.66	12	4570	2518	50598024
Neutropenia	34.85	23.66	54	4528	147911	50452631
Leukopenia	34.04	23.66	36	4546	67492	50533050
Renal tubular necrosis	33.52	23.66	17	4565	10151	50590391
Enterococcal infection	33.33	23.66	15	4567	6883	50593659
Pyrexia	33.23	23.66	92	4490	380111	50220431
Cytokine release syndrome	33.11	23.66	16	4566	8618	50591924
Thrombotic microangiopathy	32.83	23.66	16	4566	8775	50591767
Encephalitis cytomegalovirus	32.81	23.66	8	4574	534	50600008
Cytomegalovirus infection	31.85	23.66	20	4562	17942	50582600
Systemic mycosis	31.67	23.66	9	4573	1088	50599454
Anxiety disorder	31.38	23.66	12	4570	3661	50596881
Ectropion	30.29	23.66	6	4576	151	50600391
Haemophagocytic lymphohistiocytosis	30.12	23.66	15	4567	8618	50591924
Cytomegalovirus gastroenteritis	29.12	23.66	6	4576	185	50600357
Acute kidney injury	28.12	23.66	63	4519	227995	50372547
Pain	27.77	23.66	9	4573	578894	50021648
Erysipelas	27.64	23.66	13	4569	6595	50593947
Blood phosphorus decreased	27.50	23.66	11	4571	3778	50596764
Cytopenia	26.98	23.66	14	4568	8761	50591781
Pancytopenia	26.10	23.66	35	4547	83995	50516547
Malacoplakia	25.93	23.66	5	4577	109	50600433
Respiratory failure	25.35	23.66	36	4546	91145	50509397
Pleuritic pain	24.84	23.66	12	4570	6454	50594088
Mucormycosis	24.44	23.66	9	4573	2474	50598068
Acute febrile neutrophilic dermatosis	23.90	23.66	9	4573	2633	50597909
Multiple organ dysfunction syndrome	23.88	23.66	26	4556	50311	50550231

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nocardiosis	152.92	19.81	47	6124	3213	29565143
Toxoplasmosis	95.74	19.81	26	6145	1141	29567215
Febrile bone marrow aplasia	92.10	19.81	40	6131	7311	29561045
Aplastic anaemia	88.04	19.81	39	6132	7471	29560885
Cerebral toxoplasmosis	77.50	19.81	23	6148	1393	29566963
Mucosal inflammation	64.24	19.81	53	6118	31542	29536814
Respiratory failure	53.19	19.81	82	6089	97049	29471307
Cytokine release syndrome	51.97	19.81	33	6138	13086	29555270
Glomerulosclerosis	49.65	19.81	14	6157	706	29567650
Pneumocystis jirovecii pneumonia	49.16	19.81	35	6136	16744	29551612
Immune reconstitution inflammatory syndrome	47.72	19.81	26	6145	7776	29560580
Oesophagitis	47.24	19.81	30	6141	11893	29556463
Pyrexia	47.16	19.81	149	6022	287473	29280883
Botulism	46.46	19.81	10	6161	160	29568196
Pancytopenia	42.43	19.81	68	6103	83100	29485256
Kidney fibrosis	42.42	19.81	16	6155	2031	29566325
Neutropenia	41.03	19.81	87	6084	131624	29436732
Haematopoietic stem cell mobilisation	40.71	19.81	9	6162	164	29568192
Stenotrophomonas infection	37.69	19.81	14	6157	1703	29566653
Haemophagocytic lymphohistiocytosis	35.67	19.81	24	6147	10480	29557876
Graft versus host disease	35.12	19.81	23	6148	9605	29558751
Pulmonary nocardiosis	34.50	19.81	10	6161	557	29567799
Febrile neutropenia	33.61	19.81	73	6098	112167	29456189
Cytomegalovirus viraemia	33.03	19.81	19	6152	6301	29562055
Cystitis haemorrhagic	32.02	19.81	17	6154	4825	29563531
Thyroid gland abscess	29.88	19.81	6	6165	67	29568289
Generalised oedema	29.76	19.81	22	6149	11143	29557213
Infectious thyroiditis	27.99	19.81	6	6165	94	29568262
Genitourinary tract infection	27.76	19.81	6	6165	98	29568258
Face oedema	26.82	19.81	20	6151	10263	29558093
Staphylococcal bacteraemia	26.03	19.81	17	6154	7062	29561294
Bronchospasm	25.76	19.81	19	6152	9590	29558766
Bacterial toxaemia	25.45	19.81	6	6165	147	29568209
Urogenital infection bacterial	24.88	19.81	5	6166	56	29568300
Mycobacterium fortuitum infection	24.45	19.81	6	6165	175	29568181
Cytomegalovirus infection	24.27	19.81	27	6144	23188	29545168
Aspergillus infection	24.13	19.81	19	6152	10562	29557794
Parvovirus B19 infection	23.91	19.81	8	6163	716	29567640
Multiple organ dysfunction syndrome	23.55	19.81	45	6126	63071	29505285
Purpura non-thrombocytopenic	23.53	19.81	5	6166	75	29568281
Pancreatitis acute	23.19	19.81	27	6144	24358	29543998
Photodermatosis	23.14	19.81	7	6164	452	29567904
Elbow synostosis	22.74	19.81	4	6167	20	29568336
B-cell aplasia	22.18	19.81	5	6166	100	29568256
Central nervous system lesion	21.84	19.81	14	6157	5634	29562722
Tongue disorder	21.76	19.81	13	6158	4623	29563733
Death	21.40	19.81	24	6147	342060	29226296
Demodicidosis	20.74	19.81	5	6166	135	29568221
Cytomegalovirus chorioretinitis	20.37	19.81	11	6160	3227	29565129
Herpes zoster	20.21	19.81	28	6143	30024	29538332
Pulmonary necrosis	20.17	19.81	6	6165	366	29567990

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nocardiosis	246.80	18.22	69	9670	4698	64484295
Aplastic anaemia	199.06	18.22	76	9663	13844	64475149
Toxoplasmosis	186.15	18.22	48	9691	2396	64486597
Pneumocystis jirovecii pneumonia	120.60	18.22	66	9673	27568	64461425
Febrile neutropenia	109.43	18.22	138	9601	187519	64301474
Cytomegalovirus viraemia	89.60	18.22	40	9699	10788	64478205
Febrile bone marrow aplasia	88.12	18.22	40	9699	11215	64477778
Respiratory failure	86.79	18.22	114	9625	161069	64327924
Cerebral toxoplasmosis	83.50	18.22	24	9715	1802	64487191
Cytokine release syndrome	75.32	18.22	44	9695	20785	64468208
Mucosal inflammation	71.90	18.22	66	9673	62518	64426475
Pyrexia	70.46	18.22	214	9525	558430	63930563
Pancytopenia	70.45	18.22	97	9642	143212	64345781
Graft versus host disease	68.69	18.22	36	9703	13777	64475216
Neutropenia	65.31	18.22	124	9615	239500	64249493
Haemophagocytic lymphohistiocytosis	60.52	18.22	36	9703	17573	64471420
Delayed graft function	55.99	18.22	20	9719	3016	64485977
Cytomegalovirus infection	50.21	18.22	43	9696	37156	64451837
Enterococcal infection	49.35	18.22	29	9710	13837	64475156
Multiple organ dysfunction syndrome	47.34	18.22	67	9672	101346	64387647
Mycobacterium avium complex infection	43.99	18.22	18	9721	3922	64485071
Pulmonary nocardiosis	43.94	18.22	12	9727	747	64488246
Botulism	42.18	18.22	10	9729	351	64488642
Oesophagitis	42.07	18.22	31	9708	21599	64467394
Haematopoietic stem cell mobilisation	41.62	18.22	9	9730	207	64488786
Immune reconstitution inflammatory syndrome	41.56	18.22	25	9714	12445	64476548
Glomerulosclerosis	41.09	18.22	12	9727	953	64488040
Pain	39.73	18.22	17	9722	553494	63935499
Staphylococcal bacteraemia	37.76	18.22	22	9717	10333	64478660
Photodermatosis	37.58	18.22	11	9728	880	64488113
Focal myositis	37.14	18.22	6	9733	24	64488969
Hypoalbuminaemia	35.89	18.22	26	9713	17648	64471345
Optic neuritis	34.32	18.22	19	9720	8097	64480896
Pulmonary mucormycosis	34.14	18.22	10	9729	802	64488191
Escherichia bacteraemia	32.45	18.22	16	9723	5387	64483606
Cryptosporidiosis infection	31.81	18.22	9	9730	638	64488355
Thyroid gland abscess	31.04	18.22	6	9733	77	64488916
Stenotrophomonas infection	30.77	18.22	13	9726	3067	64485926
Kidney fibrosis	30.69	18.22	13	9726	3088	64485905
Antithrombin III	30.36	18.22	6	9733	87	64488906
Rhodococcus infection	29.63	18.22	7	9732	242	64488751
Fall	29.56	18.22	13	9726	416813	64072180
Lymphopenia	29.32	18.22	27	9712	25630	64463363
Acute kidney injury	28.82	18.22	139	9600	449101	64039892
Infectious thyroiditis	28.59	18.22	6	9733	119	64488874
Thrombotic microangiopathy	28.25	18.22	22	9717	16633	64472360
Dizziness	28.10	18.22	15	9724	430148	64058845
Adenovirus infection	28.01	18.22	16	9723	7239	64481754
Mucormycosis	27.83	18.22	16	9723	7325	64481668
Fatigue	27.78	18.22	44	9695	748686	63740307
Cytopenia	27.47	18.22	21	9718	15450	64473543
Bone marrow failure	27.43	18.22	35	9704	47917	64441076
Bacterial toxaemia	27.00	18.22	6	9733	157	64488836
Graft versus host disease in skin	26.76	18.22	14	9725	5333	64483660
Brain oedema	26.73	18.22	24	9715	22051	64466942
Cystitis haemorrhagic	26.64	18.22	16	9723	7940	64481053
Neutrophil count decreased	26.16	18.22	44	9695	77152	64411841
Blood phosphorus decreased	25.91	18.22	14	9725	5691	64483302
Venoocclusive liver disease	25.66	18.22	17	9722	9998	64478995
Mycobacterium fortuitum infection	25.43	18.22	6	9733	206	64488787
Acanthamoeba infection	24.98	18.22	7	9732	479	64488514
Aspergillus infection	24.29	18.22	20	9719	16359	64472634
Genitourinary tract infection	24.13	18.22	6	9733	258	64488735
Urogenital infection bacterial	24.08	18.22	5	9734	94	64488899
Pancreatitis acute	24.07	18.22	31	9708	42824	64446169
Encephalitis cytomegalovirus	23.88	18.22	8	9731	997	64487996
Bronchospasm	23.20	18.22	22	9717	21660	64467333
Hyperuricaemia	23.02	18.22	16	9723	10175	64478818
Ectropion	22.25	18.22	6	9733	356	64488637
Parvovirus B19 infection	22.24	18.22	8	9731	1231	64487762
Demodicidosis	21.88	18.22	5	9734	149	64488844
Toxicity to various agents	21.85	18.22	14	9725	363499	64125494
Disseminated toxoplasmosis	21.78	18.22	5	9734	152	64488841
B-cell aplasia	21.69	18.22	5	9734	155	64488838
Bronchopulmonary aspergillosis	21.64	18.22	20	9719	19065	64469928
Arthralgia	21.59	18.22	21	9718	442239	64046754
Candida infection	21.31	18.22	25	9714	31394	64457599
Cytomegalovirus gastroenteritis	21.24	18.22	6	9733	423	64488570
Thrombocytopenia	21.14	18.22	78	9661	223723	64265270
Central nervous system lesion	20.85	18.22	16	9723	11833	64477160
Systemic mycosis	20.56	18.22	9	9730	2314	64486679
Pulmonary necrosis	20.40	18.22	6	9733	488	64488505
Purpura non-thrombocytopenic	20.20	18.22	5	9734	211	64488782
Staphylococcal infection	20.05	18.22	31	9708	50647	64438346
Myocarditis toxoplasmal	19.99	18.22	4	9735	62	64488931
Weight increased	19.91	18.22	4	9735	213344	64275649
Micrococcal sepsis	19.81	18.22	4	9735	65	64488928
Hepatocellular injury	19.79	18.22	29	9710	45206	64443787
Malacoplakia	19.51	18.22	5	9734	243	64488750
Death	19.18	18.22	27	9712	482678	64006315
Malaise	19.12	18.22	19	9720	396228	64092765
Septic shock	18.78	18.22	46	9693	105391	64383602
Otitis media	18.42	18.22	11	9728	5402	64483591

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	P01CX01	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS Other agents against leishmaniasis and trypanosomiasis
FDA EPC	N0000175485	Antiprotozoal
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000981	Antiprotozoal Agents
MeSH PA	D014344	Trypanocidal Agents
CHEBI has role	CHEBI:36335	trypanocidal drugs
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35718	antifungal agents
CHEBI has role	CHEBI:60643	N-methyl-D-aspartate receptor antagonists
CHEBI has role	CHEBI:63673	CCR5 antagonist
CHEBI has role	CHEBI:67079	anti-inflammatory agents
CHEBI has role	CHEBI:76395	histone acetyltransferase inhibitors
CHEBI has role	CHEBI:136651	S100 calcium-binding protein B inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
African trypanosomiasis	indication	27031003	DOID:10112
Pneumocystosis jiroveci pneumonia	indication	415125002	DOID:11339
Pneumocystis Carinii Pneumonia Prevention	indication
Visceral leishmaniasis	off-label use	186803007	DOID:9146
Cutaneous leishmaniasis	off-label use	240637006	DOID:9111
Hypocalcemia	contraindication	5291005
Hyperkalemia	contraindication	14140009
Torsades de pointes	contraindication	31722008
Dehydration	contraindication	34095006
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Asthma	contraindication	195967001	DOID:2841
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Toxic nephropathy	contraindication	236514003
Hypoglycemic disorder	contraindication	237630007
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.38	Basic
pKa2	10.78	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	Ki	6.29	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN	Ki	4.89	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	Ki	5.66	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	Ki	6.33	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	Ki	5.77	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	Ki	5.87	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	Ki	6.30	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	Ki	6.66	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN	Ki	5.68	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	Ki	5.60	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	Ki	6.31	DRUG MATRIX
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN	IC50	6.10	DRUG MATRIX
Plasminogen	Enzyme	P00747	PLMN_HUMAN	IC50	5.44	CHEMBL
Trypsin-1	Enzyme	P07477	TRY1_HUMAN	Ki	5.64	CHEMBL
Coagulation factor X	Enzyme	P00742	FA10_HUMAN	IC50	4.98	CHEMBL
Suppressor of tumorigenicity 14 protein	Enzyme	Q9Y5Y6	ST14_HUMAN	Ki	5.94	CHEMBL
Protein S100-B	Cytosolic other	P04271	S100B_HUMAN	Kd	6	CHEMBL
Protein arginine N-methyltransferase 1	Enzyme	Q99873	ANM1_HUMAN	IC50	4.09	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN	IC50	4.66	CHEMBL
Amiloride-sensitive amine oxidase [copper-containing]	Enzyme	P19801	AOC1_HUMAN	Ki	6.54	CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN	IC50	5.92	CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN	IC50	6.39	CHEMBL
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN	IC50	5.57	CHEMBL
Solute carrier family 22 member 3	Transporter	O75751	S22A3_HUMAN	IC50	5.02	CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2A	Ion channel	Q05586 Q12879	NMDZ1_HUMAN NMDE1_HUMAN	IC50	6.14	CHEMBL
Spermidine/spermine N(1)-acetyltransferase 1	Enzyme	P21673	SAT1_HUMAN	Ki	5.70	CHEMBL
Protein-tyrosine phosphatase 4A3	Enzyme	O75365	TP4A3_HUMAN	IC50	4.27	CHEMBL
Protein tyrosine phosphatase type IVA 2	Enzyme	Q12974	TP4A2_HUMAN	IC50	6.52	CHEMBL
Protein tyrosine phosphatase type IVA 1	Enzyme	Q93096	TP4A1_HUMAN	IC50	6.52	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT	Ki	6.27	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT	IC50	5.92	CHEMBL
Glutamate NMDA receptor	Ion channel		NMDZ1_RAT NMDE1_RAT NMDE2_RAT NMDE3_RAT NMDE4_RAT NMD3B_RAT NMD3A_RAT	IC50	5.88	CHEMBL
Acrosin	Enzyme		ACRO_PIG	Ki	5.64	CHEMBL
Protein S100-B	Unclassified		S100B_RAT	Kd	4.36	CHEMBL

External reference:

ID	Source
4019043	VUID
N0000178948	NUI
D00834	KEGG_DRUG
140-64-7	SECONDARY_CAS_RN
4019043	VANDF
4019881	VANDF
C0030863	UMLSCUI
CHEBI:45081	CHEBI
CHEMBL55	ChEMBL_ID
CHEMBL361506	ChEMBL_ID
DB00738	DRUGBANK_ID
CHEMBL935	ChEMBL_ID
D010419	MESH_DESCRIPTOR_UI
4735	PUBCHEM_CID
4167	INN_ID
6823-79-6	SECONDARY_CAS_RN
673LC5J4LQ	UNII
7994	RXNORM
2196	MMSL
5250	MMSL
7933	MMSL
d00030	MMSL
002971	NDDF
16826009	SNOMEDCT_US
31692006	SNOMEDCT_US
372699006	SNOMEDCT_US
PNT	PDB_CHEM_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pentamidine Isethionate	HUMAN PRESCRIPTION DRUG LABEL	1	13925-515	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAMUSCULAR	ANDA	13 sections
Pentamidine Isethionate	HUMAN PRESCRIPTION DRUG LABEL	1	13925-522	INHALANT	300 mg	RESPIRATORY (INHALATION)	ANDA	21 sections
pentamidine isethionate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-748	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAMUSCULAR	ANDA	17 sections
PENTAMIDINE ISETHIONATE	HUMAN PRESCRIPTION DRUG LABEL	1	39822-3050	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAVENOUS	ANDA	22 sections
Pentam 300	HUMAN PRESCRIPTION DRUG LABEL	1	63323-113	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAMUSCULAR	NDA	13 sections
NebuPent	Human Prescription Drug Label	1	63323-877	INHALANT	300 mg	RESPIRATORY (INHALATION)	NDA	12 sections